{"id":"NCT00561080","sponsor":"Merck Sharp & Dohme LLC","briefTitle":"Immunogenicity and Safety of a 1-dose Regimen of a Zoster Vaccine Versus Different 2-dose Regimens in Participants ≥ 70 Years of Age. (V211-043)","officialTitle":"An Open-label, Randomised, Comparative, Multi-centre Study of the Immunogenicity and Safety of a 1-dose Regimen and Different 2-dose Regimens of a Zoster Vaccine (Live), ZOSTAVAX ®, in Subjects ≥ 70 Years of Age","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2007-10-26","primaryCompletion":"2009-06-03","completion":"2009-06-03","firstPosted":"2007-11-20","resultsPosted":"2017-12-22","lastUpdate":"2019-01-11"},"enrollment":759,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"NONE","primaryPurpose":"PREVENTION"},"conditions":["Prevention of : Herpes-Zoster"],"interventions":[{"type":"BIOLOGICAL","name":"Zostavax","otherNames":["Zoster vaccine live"]}],"arms":[{"label":"Single Dose of Zostavax","type":"EXPERIMENTAL"},{"label":"Zostavax - Day 0 and Month 1","type":"EXPERIMENTAL"},{"label":"Zostavax - Day 0 and Month 3","type":"EXPERIMENTAL"}],"summary":"Primary objective:\n\nImmunogenicity To demonstrate that a second dose of ZOSTAVAX® elicits higher varicella-zoster virus (VZV) antibody titres than a first dose of ZOSTAVAX® whether given as a 0-1 month schedule or as a 0-3 month schedule in subjects ≥70 years of age as measured at 4 weeks post-vaccination\n\nSecondary objectives Immunogenicity\n\n* To summarise the VZV antibody titres at 4 weeks post-vaccination after a 1-dose regimen and 4 weeks post-vaccination after each dose of each 2-doses regimen of ZOSTAVAX®.\n* To compare the VZV antibody titres at 12 months after completion of a 1-dose regimen with the VZV antibody titres at 12 months after completion of each 2-doses regimen of ZOSTAVAX®\n* To summarise the VZV antibody titres at 24 and 36 months after completion of a 1-dose regimen and at 24 and 36 months after completion of each 2-doses regimen of ZOSTAVAX®","primaryOutcome":{"measure":"Geometric Mean Titer (GMT) of Varicella Zoster Virus (VZV) Antibodies 4 Weeks After Each Vaccination: Groups 2 and 3","timeFrame":"4 weeks post-dose 1 (Month 1 for all groups) and 4 weeks post-dose 2 (Month 2 for Group 2 and Month 4 for Group 3)","effectByArm":[{"arm":"Group 2: Zostavax - Day 0 and Month 1","deltaMin":498.8,"sd":null},{"arm":"Group 3: Zostavax - Day 0 and Month 3","deltaMin":523.3,"sd":null}],"pValues":[{"comp":"OG000","p":"0.948"},{"comp":"OG001","p":">0.999"}]},"eligibility":{"minAge":"70 Years","sex":"ALL","healthyVolunteers":true,"inclusionCount":null,"exclusionCount":null},"locations":{"siteCount":0,"countries":[]},"refs":{"pmids":["23319176"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":4,"n":253},"commonTop":["Injection site erythema","Injection site swelling","Injection site pain","Headache"]}}